Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Status unconfirmed · Not applicable

Conditions studied: Cardiomyopathies, Heart Failure

In brief

The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.

Key facts

Study ID

NCT04504188

Run by

Zoll Medical Corporation

People needed

300

Starts

2021-03-08

Expected to finish

2024-12-01

Last updated by the study team

2024-07-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• TriHealth Hatton Research Institute — Cincinnati, Ohio, United States (enrolling)
• CardioVoyage — McKinney, Texas, United States (enrolling)
• Texas Cardiology Associates of Houston — Kingwood, Texas, United States
• CAMC — Charleston, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.